Given the recent FDA approval expansion for Sarepta's Elevidys and the projected revenue growth in the gene therapy market, I believe that SRPT is poi...
Read
More
Given the recent FDA approval expansion for Sarepta's Elevidys and the projected revenue growth in the gene therapy market, I believe that SRPT is poised for significant price appreciation as its market potential continues to expand, making it a strong long-term investment opportunity.
This idea is based on unusual options activity + it's important to note that this is a thinly traded name so consider playing shares instead of option...
Read
More
This idea is based on unusual options activity + it's important to note that this is a thinly traded name so consider playing shares instead of options if you want to play. As long as 136.25 holds I like this one for a move into 142 ahead; BUT if it fails to hold support then this idea fails.